Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.49 |
| ▸ | CTSS | P25774 | 9/20 | 0.41 |
| ▸ | CTSL | P07711 | 9/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044582 | 0.92 | CTSK (0.40) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4045678 | 0.91 | CTSK (0.49) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4046943 | 0.88 | CTSK (0.50) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4044864 | 0.88 | CTSK (0.43) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4043689 | 0.85 | CTSK (0.51) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4050228 | 0.85 | CTSK (0.49) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4046025 | 0.85 | CTSK (0.49) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4045333 | 0.85 | CTSK (0.53) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4050120 | 0.84 | CTSK (0.51) | CTSKCTSSCTSLCTSBKDM4E | |
| SCHEMBL4045412 | 0.84 | CTSK (0.48) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483273-B1 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | BERENS ULRICH | 2006-10-26 | — | — | US | disclosed |
| US-7094907-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20040260091-A1 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2004-12-23 | — | — | US | disclosed |
| EP-1483273-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | Solvias AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003031456-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | NR2E3, WNK2, OXSR1 | CTSK 4836/4885CTSS 4874/4885CTSL 4885/4885 |
| US-20040260091-A1 | Ligands for asymmetric reactions | COASY, ICMT, AP2M1 | CTSK 2078/4885CTSS 670/4885CTSL 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.